In patients requiring the concurrent use of statins and CYP3A4 inhibitors , pravastatin , fluvastatin , and rosuvastatin carry the lowest risk of drug interactions ; atorvastatin carries moderate risk , whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors .
O B-OrganismTaxon O O O O O B-ChemicalEntity O B-GeneOrGeneProduct O O B-ChemicalEntity O B-ChemicalEntity O O B-ChemicalEntity O O O O O O O O B-ChemicalEntity O O O O O B-ChemicalEntity O B-ChemicalEntity O O O O O O O O O B-OrganismTaxon O O B-ChemicalEntity I-ChemicalEntity O